Healthcare -
Biotechnology - NASDAQ - US
$ 3.02
2.72 %
$ 169 M
Market Cap
-2.36
P/E
1. INTRINSIC VALUE
Balance Sheet
Spero Therapeutics, Inc.
| Current Assets | 107 M |
| Cash & Short-Term Investments | 52.9 M |
| Receivables | 52.5 M |
| Other Current Assets | 1.91 M |
| Non-Current Assets | 3.27 M |
| Long-Term Investments | 0 |
| PP&E | 3.11 M |
| Other Non-Current Assets | 153 K |
| Current Liabilities | 49.1 M |
| Accounts Payable | 7.31 M |
| Short-Term Debt | 3.49 M |
| Other Current Liabilities | 38.3 M |
| Non-Current Liabilities | 15.3 M |
| Long-Term Debt | 2.55 M |
| Other Non-Current Liabilities | 12.8 M |
EFFICIENCY
Earnings Waterfall
Spero Therapeutics, Inc.
| Revenue | 27.4 M |
| Cost Of Revenue | 2 K |
| Gross Profit | 27.4 M |
| Operating Expenses | 101 M |
| Operating Income | -73.4 M |
| Other Expenses | -4.8 M |
| Net Income | -68.6 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Spero Therapeutics, Inc.
| Net Income | -68.6 M |
| Depreciation & Amortization | 2 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 7.79 M |
| Change in Working Capital | 36.3 M |
| Others | 32.9 M |
| Free Cash Flow | -23.4 M |
Wall Street Analysts Price Targets
Spero Therapeutics, Inc.
SPRO has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
0.015 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Spero Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
235 K USD 4
6-9 MONTHS
53 K USD 1
9-12 MONTHS
57.3 K USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results
Based on the positive results of the registrational Phase 3 PIVOT-PO study, Tebipenem is expected to be approved under the SPA in mid-2026. Spero will not bear any costs or risks since GSK, as a license partner, will take over commercialization. Approval is expected to trigger in total of $175 million in milestone payments over the next 12 months.
seekingalpha.com
- 2 weeks ago
Squarepoint Ops LLC Buys Shares of 55,051 Spero Therapeutics, Inc. (NASDAQ:SPRO)
Squarepoint Ops LLC bought a new stake in Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 55,051 shares of the company’s stock, valued at approximately $57,000. Squarepoint Ops LLC owned approximately 0.10% of Spero Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Other institutional investors and hedge funds also recently made changes to their positions in the company. Monimus Capital Management LP acquired a new position in Spero Therapeutics during the fourth quarter worth $320,000. Renaissance Technologies LLC boosted its holdings in Spero Therapeutics by 13.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,105,591 shares of the company’s stock worth $1,139,000 after purchasing an additional 130,938 shares during the last quarter. Anson Funds Management LP boosted its holdings in Spero Therapeutics by 2.4% during the fourth quarter. Anson Funds Management LP now owns 3,839,886 shares of the company’s stock worth $3,955,000 after purchasing an additional 89,436 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Spero Therapeutics by 26,011.9% during the fourth quarter. JPMorgan Chase & Co. now owns 61,624 shares of the company’s stock worth $63,000 after purchasing an additional 61,388 shares during the last quarter. Finally, ADAR1 Capital Management LLC boosted its holdings in Spero Therapeutics by 7.8% during the fourth quarter. ADAR1 Capital Management LLC now owns 801,277 shares of the company’s stock worth $825,000 after purchasing an additional 57,818 shares during the last quarter. Institutional investors and hedge funds own 25.60% of the company’s stock. Spero Therapeutics Trading Up 3.3% NASDAQ SPRO opened at $2.85 on Wednesday. The firm’s fifty day moving average price is $1.04 and its two-hundred day moving average price is $0.96. Spero Therapeutics, Inc. has a 1 year low of $0.51 and a 1 year high of $2.95. The firm has a market capitalization of $159.35 million, a P/E ratio of 40.72 and a beta of 1.31. Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.30. Spero Therapeutics had a net margin of 3.30% and a return on equity of 4.03%. The business had revenue of $5.87 million for the quarter, compared to analyst estimates of $11.00 million. On average, research analysts anticipate that Spero Therapeutics, Inc. will post -1.2 EPS for the current fiscal year. About Spero Therapeutics (Free Report) Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.
https://www.defenseworld.net
- 2 weeks ago
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal
SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.
zacks.com
- 3 weeks ago
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for efficacy.
benzinga.com
- 4 weeks ago
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually in the US 1 with many cases requiring hospitalization, contributing to over $6 billion per year in healthcare costs 2 Data from the PIVOT-PO trial to be part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 that Spero's development partner, GSK, intends to submit CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), including pyelonephritis, met its primary endpoint and will stop early for efficacy (NCT06059846).3 The decision follows a recommendation from an Independent Data Monitoring Committee (IDMC) that completed a pre-specified interim analysis of data from 1,690 patients enrolled in the trial.
globenewswire.com
- 4 weeks ago
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.24 per share a year ago.
zacks.com
- 1 month ago
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.
globenewswire.com
- 1 month ago
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close.
globenewswire.com
- 1 month ago
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero's 2025 annual meeting of stockholders. Since January 2025, Ms. Rajavelu has been serving as Spero's Interim President and Chief Executive Officer, and has served as Chief Financial Officer, Treasurer, and Chief Business Officer since November 2023. She will continue to serve as the Company's Chief Financial Officer and Treasurer.
globenewswire.com
- 1 month ago
Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Shai Biran - Senior Director Investor Relations Esther Rajavelu - Interim Chief Executive Officer, Chief Financial Officer Tim Keutzer - Chief Operating Officer Conference Call Participants Gavin Clarke-Gartner - Evercore ISI Athena Chin - TD Cowen Operator Good afternoon, and welcome to the Spero Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in listen-only-mode.
seekingalpha.com
- 2 months ago
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $0.96 per share a year ago.
zacks.com
- 2 months ago
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update
CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.
globenewswire.com
- 2 months ago
8. Profile
Summary
Spero Therapeutics, Inc. SPRO
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 169 M
Dividend Yield
0.00%
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Contact
675 Massachusetts Avenue, Cambridge, MA, 02139
https://sperotherapeutics.com
IPO
Date
Nov. 2, 2017
Employees
32
Officers
Dr. David Hong
Senior Vice President of Clinical Development
Ms. Esther P. Rajavelu
Chief Executive Officer, Chief Financial Officer, President & Treasurer
Dr. Ankit Mahadevia M.D., MBA
Co-Founder & Director
Mr. John Raymond
Senior Vice President of Finance & Business Operations
Mr. Timothy Keutzer
Chief Operating Officer
Mr. James P. Brady
Chief Human Resource Officer
Ms. Sheila Finan
Senior Vice President of Controller